1. Fletcher CV, Kakuda TN, Anderson PL, Henry K, Schacker T, Brundage RC. Viral dynamics of concentration-targeted vs standard dose therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, CA (abstr 322)
2. Burger DM, Hugen PWH, Droste J, Huitema ADR. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) 1250 mg BID in treatment-naive patients improves therapeutic outcome after 1 year: results from ATHENA. Presented at: 2nd International Workshop on Clinical Pharmacology of HIV Therapy. 2–4 April 2001. Noordwijk, Netherlands (abstr 6.2a).
3. Aarnoutse R, Burger D, Verweij-Van Wissen C, Van Ewijk-Beneken Kolmer E, Wuis E, Kehster Y. An international interlaboratory quality control (QC) program for therapeutic drug monitoring (TDM) in HIV infection. Presented at: 8th Conference on Retroviruses and Opportunistic Infections. February 5–8, 2001. Chicago, IL (abstr 734).
4. Serum and plasma drug levels of amprenavir display limited inter-and intra- patient variability;Luber;AIDS,2000
5. Long-term stability of nelfinavir mesylate in human plasma;Turner;Clin Chem,2000